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A B S T R A C T
In addition to tissues such as liver, the plasma membrane sodium-dependent citrate transporter, NaCT
(SLC13A5), is highly expressed in brain neurons, but its function is not understood. Loss-of-function mutations in
the human SLC13A5 gene have been associated with severe neonatal encephalopathy and pharmacoresistant
seizures. The molecular mechanisms of these neurological alterations are not clear. We performed a detailed
examination of a Slc13a5 deletion mouse model including video-EEG monitoring, behavioral tests, and elec-
trophysiologic, proteomic, and metabolomic analyses of brain and cerebrospinal fluid. The experiments revealed
an increased propensity for epileptic seizures, proepileptogenic neuronal excitability changes in the hippo-
campus, and significant citrate alterations in the CSF and brain tissue of Slc13a5 deficient mice, which may
underlie the neurological abnormalities. These data demonstrate that SLC13A5 is involved in brain citrate
regulation and suggest that abnormalities in this regulation can induce seizures. The present study is the first to
(i) establish the Slc13a5-knockout mouse model as a helpful tool to study the neuronal functions of NaCT and
characterize the molecular mechanisms by which functional deficiency of this citrate transporter causes epilepsy
and impairs neuronal function; (ii) evaluate all hypotheses that have previously been suggested on theoretical
grounds to explain the neurological phenotype of SLC13A5 mutations; and (iii) indicate that alterations in brain
citrate levels result in neuronal network excitability and increased seizure propensity.
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1. Introduction
SLC13A5, also known as the Na+/citrate cotransporter (NaCT) and
encoded by the Slc13a5 gene in mammals, is a Na+-coupled transporter
for citrate that is expressed in the plasma membrane of cells particularly
in the liver, testis, and brain (Bergeron et al., 2013; Willmes et al.,
2013; Pajor, 2014). SLC13A5 mediates the uptake of tricarboxylic acid
cycle (TCA) intermediates such as citrate, succinate, and α-ketogluta-
rate into cells across the plasma membrane. Reducing the expression of
the Slc13a5 homolog in D. melanogaster and C. elegans significantly
extends life span and promotes mitochondrial biogenesis by mechan-
isms akin to caloric restriction (Rogina et al., 2000; Anderson and
Weindruch, 2012). Therefore, the Drosophila gene has been named
‘INDY’, an acronym for ‘I'm Not Dead, Yet’ (Rogina et al., 2000).
In the mouse brain, SLC13A5 is expressed in neurons of the cerebral
cortex, hippocampal formation, cerebellum, and olfactory bulb (Inoue
et al., 2002a; Wada et al., 2006; Pajor et al., 2001). In the cerebral
cortex of rats, neuronal Slc13a5 expression is known to increase during
postnatal development, reaching much higher levels in adult animals
(Yodoya et al., 2006). SLC13A5 is also expressed in neurons of the
human brain (Inoue et al., 2002b; Bhutia et al., 2017), however, the
potential role of SLC13A5 for neuronal excitability or functionality is
presently not known (Bergeron et al., 2013; Bhutia et al., 2017). In
mice, but not rats, SLC13A5 has also been detected in astrocytes (Pajor,
2014).
The interest in the activity of SLC13A5 and other plasma membrane
transporters of TCA cycle intermediates in the brain is driven in part by
the assumption that neurons do not express pyruvate carboxylase
(Cesar and Hamprecht, 1995). Therefore, neurons should not be able to
synthesize TCA intermediates de novo. Further, plasma membrane
transporters of TCA cycle intermediates are assumed to be important for
maintaining normal metabolism (Yu et al., 1983; Shank et al., 1985;
Cesar and Hamprecht, 1995). Interestingly, despite the lack of pyruvate
carboxylase, normal neuronal pyruvate carboxylation rates have been
described that resemble those seen in glial cells (Hassel and Brathe,
2000; Hassel, 2001). The pathway by which neurons synthesize TCA
cycle intermediates is not yet understood.
Recently discovered loss-of-function mutations in the human
SLC13A5 gene have been linked to the development of early-onset
epileptic encephalopathy. Affected individuals can have recurrent and
pharmacoresistant seizures as early as the first day of life (Thevenon
et al., 2014; Hardies et al., 2015; Klotz et al., 2016; Bainbridge et al.,
2017; Schossig et al., 2017; Weeke et al., 2017; Alhakeem et al., 2018;
Grinspan et al., 2018). The clinical presentation ranges from multiple
daily focal or generalized convulsive seizures, to life-threatening status
epilepticus to rare seizures with rather tonic-static impairment, even in
patients with the same homozygous mutations; heterozygous carriers
are not affected. Functional transport studies in vitro for over a dozen
different mutations in SLC13A5 showed little to no transport activity,
suggesting a loss of function (Klotz et al., 2016; Selch et al., 2018). Yet,
the exact molecular mechanisms by which the functional deficiency of
SLC13A5 may lead to epilepsy and impairs neuronal development and
function remain to be elucidated. Interestingly, there is as yet no evi-
dence of epilepsy or encephalopathy in Slc13a5-knockout mice (Bhutia
et al., 2017), but it is not known whether this relates to species dif-
ferences in clinical consequences of the loss of function of this trans-
porter, or to a lack of sufficiently detailed neurological analysis of the
Slc13a5-knockout mice. Here, we performed detailed neurological,
behavioral, electrophysiological, metabolomic and proteomic brain
analyses in a mouse model of Slc13a5 deficiency, including continuous
video-EEG monitoring. We recorded epileptic seizures in a fraction of
the Slc13a5-knockout mice, thus allowing to assess the role of Slc13a5
in the development of epileptic seizures and to delineate possible mo-
lecular mechanisms.
2. Materials and methods
2.1. Animals
The Slc13a5−/− mice (knockout-mouse model of the mammalian
INDY [SLC13A5] homolog, SLC13A5) were generated on a C57BL/6J
background as described previously (Birkenfeld et al., 2011). The mice
were bred at the Research Institutes for Experimental Medicine of the
Charité Berlin and/or the experimental center of the Medical Faculty
Carl Gustav Carus of the Technische Universität Dresden, Germany and
shipped to the laboratories in Hannover (video-EEG monitoring, be-
havioral analyses, histology) and Rostock (electrophysiology). For
metabolomic and proteomic analyses, brain tissue, CSF and plasma
were sampled in Dresden and samples were shipped to San Diego and
Munich.
Experiments were performed according to the EU council directive
2010/63/EU and the German Law on Animal Protection
(“Tierschutzgesetz”). Ethical approval for the study was granted by an
ethical committee (according to §15 of the Tierschutzgesetz) and the
government agency (Lower Saxony State Office for Consumer
Protection and Food Safety; LAVES) responsible for approval of animal
experiments in Saxony (reference number: TVV5/2016) and Lower
Saxony (reference number: 16/2226). All efforts were made to mini-
mize both the suffering and the number of animals.
Slc13a5-knockout and littermate control male and female mice were
housed separately in groups under controlled environmental conditions
(231°C; 50–60% humidity; 12 h light/dark cycle; light on at 6:00 a.m.)
with free access to standard laboratory chow and tap water. Mice were
allowed to adapt to the laboratory conditions before experiments were
started. Experiments started at an age of 7 weeks (video/EEG mon-
itoring), 10–12 weeks (behavioral analyses, metabolomics, proteomics),
or 14–15 weeks (electrophysiology).
For tissue, CSF and plasma sampling, mice were fasted 4 h in the
morning and CSF punctuation or sacrificing was performed. All animal
experiments of this study are reported in accordance with ARRIVE
guidelines (Kilkenny et al., 2010).
2.2. Hippocampal electrode implantation in mice
Bipolar electrodes for the recording of electroencephalograms
(EEGs) were stereotactically implanted into the right CA1 area of the
dorsal hippocampus in 20 mice (5 mice each for male and female
wildtype and knock out, respectively). Stereotaxic coordinates for EEG
electrode implantation are shown in Table S1. In preliminary experi-
ments in groups of 4 mice, stereotaxic coordinates (according to
Paxinos and Franklin (2001) were determined for each genotype and
sex by histological verification of the implantation site in the CA1. The
surgery was performed under anesthesia with ketamine (70 mg/kg i.p.;
Ketamin 10%, Medistar, Ascheberg, Germany) and xylazine (14 mg/
kg i.p.; Rompun® 2% Bayer, Monheim, Germany). To prevent post-
operative infection, mice were treated with marbofloxacin (4 mg/
kg s.c., once daily; Marbocyl FD 1%, Vetoquinol, Ravensburg, Ger-
many) for 7 days starting two days before electrode implantation.
2.3. EEG monitoring in mice
Starting one week after the surgery, 8 wildtype (Slc13a5+/+) and 8
knock out (Slc13a5−/−) mice were connected to a system consisting of
one-channel amplifiers (Animal BioAmp FE136, ADInstruments Ltd.,
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Sydney, Australia) and analogue-digital converters (PowerLab 4/35
PL3504/P, ADInstruments) for two weeks of continuous (24 h/day)
EEG-monitoring. The data were recorded and analyzed with the
LabChart 8 software for windows (ADInstruments; sampling rate
200 Hz; time constant 0.1 s; low pass filter 60 Hz). The EEG recording
was directly linked to simultaneous digital video-recording of four mice
per screen using four infrared board cameras (Sony) merged by one
video quad processor (Monarcor TVSP-44COL). Mice were housed in
clear plexiglass cages (one per cage) with light-colored bedding. For
monitoring during the dark phase, infrared LEDs were mounted above
the cages.
Every second day of the two weeks of video/EEG recordings was
visually analyzed for abnormal electrographic activity, i.e. occurrence
of spikes, electrographic or electroclinical seizures and other abnormal
activities, by two experimenters blinded to the genotype and sex.
Careful comparison of any EEG abnormality with the concomitant
video allowed to exclude that the abnormality was an artifact, e.g., due
to chewing, grooming, scratching or other intense movements of the
animal, which can sometimes mimic ictiform EEG activity (Anjum
et al., 2018).
Seizure activity in humans affected by loss of function mutation of
Slc13a5 ranges from subclinical to polymorphic clinical seizures
(Hardies et al., 2015). Therefore, any kind of deviation from a phy-
siological rodent hippocampal EEG (i.e., normal control EEG activity
without any paroxysmal alterations, usually typical theta rhythm with
rhythmic slow wave activity, 6–9 Hz [Twele et al., 2017]) that could
not be verified as an artifact was noted (see Results). The severity of
electroclinical seizures was rated by a modified Racine scale (Racine,
1972), in which score 1 was behavioral arrest (associated with parox-
ysmal EEG activity), score 2 was myoclonic activity (with paroxysmal
EEG activity), and score 5 was generalized convulsive seizure activity
(with paroxysmal EEG activity).
2.4. Pentylenetetrazole (PTZ) seizure threshold
Thirteen wildtype (Slc13a5+/+), 14 heterozygote (Slc13a5+/−),
and 12 knock out (Slc13a5−/−) mice were used for seizure threshold
determination. The threshold for PTZ-induced seizures was determined
by timed intravenous (i.v.) infusion of a 1% solution of PTZ via flexible
tubing placed into the tail vein of mice at a rate of 0.3 ml/min with an
infusion pump (Syringe Infusion Pump 22, Harvard Apparatus) as de-
scribed previously (Töllner et al., 2016). All PTZ seizure threshold de-
terminations were performed at the same time of the day (8 am to
1 pm).
2.5. Behavioral tests
At the age of 10 to 12 weeks all mice underwent all behavioral tests
described in the following at the same sequence of tests. The sequence
of tests was organized from the least to the most aversive, with an inter-
test interval of usually 1 week. Overall, the various tests were per-
formed over a period of four weeks. All behavioral tests were carried
out under artificial light and controlled conditions of temperature
(22 ± 0.5 °C) and humidity (55 ± 5%). For each of the in vivo tests
performed, all animals were tested at the same time of the day, i.e.,
Morris water maze, and novelty-induced hypophagia were performed in
the morning (8 am to 1 pm); Irwin Screen and rotarod were carried out
in the afternoon (1 to 4 pm).
A modified version of the Irwin observation test (Irwin, 1968),
which comprises a battery of single tests evaluating general health,
physiologic parameters and reflexes, and neuronal and behavioral ab-
normalities (for details see Klee et al. (2015), was used as a screen to
evaluate alterations in behavior and physiological function in 15
wildtype (Slc13a5+/+) and 15 knock out (Slc13a5−/−) mice. In a
modified hanging wire test (Coughenor et al., 1977) for evaluating
balance and catalepsy, mice were put upon a grid, which was rotated by
180° with a cut-off after 5 s. Each measure was scored using a rating
system from score 0 up to 5 with score 2 representing “normal” ap-
pearance, behavior or reaction. Motor performance impairment was
also assessed in the rotarod test (Dunham and Miya, 1957) where mice
had to walk on a turning rod (6 rpm) for 60 s.
The Morris water maze test (Morris, 1984), in which rodents learn
to escape from water onto a hidden platform, was used to evaluate
visual-spatial memory and hippocampal integrity in 15 wildtype
(Slc13a5+/+) and 15 knock out (Slc13a5−/−) mice as described pre-
viously (Müller et al., 2009).
The conflict between exploratory behavior and anxiety was assessed
in the novelty-induced hypophagia test (Bodnoff et al., 1988; Shephard
and Broadhurst, 1982), which measures the diminished feeding beha-
vior of rodents in response to a novel environment. In the present study,
the mice were fed with palatable snacks in their home cages for seven
consecutive days. For the test day, 16 wildtype (Slc13a5+/+), 16 het-
erozygote (Slc13a5+/−), and 14 knockout (Slc13a5−/−) mice were
placed into a white illuminated square arena (60 × 60 cm, 150–180 lx
in corners/center) with a palatable snack in the center. The area was
further divided into an inner zone (36 × 36 cm) and an outer zone. The
software Ethovision was used to track animals and to analyze para-
meters such as the latency to consume the palatable snack, velocity,
distance moved, time spent in the different zones. Grooming, rearing,
urine and defecation were counted manually by two experimenters
blinded to the treatment.
2.6. Brain histology
To detect any obvious alterations in morphology and histology of
brain regions in Slc13a5−/− mice, particularly in the hippocampus,
from which EEG recordings had been performed, thionin staining was
performed. At the end of the in vivo experiments, the mice were an-
esthetized and perfused with paraformaldehyde. Series of coronal brain
sections (40 μm) were prepared for histology as described previously
(Bröer et al., 2016). To analyze differences in myelination, Luxol Fast
Blue (LFB) staining on coronal 12 μm cryo-slices of the brain from mice
used for CSF sampling were performed. Littermate Slc13a5+/+ mice
were used for comparison.
2.7. In-vitro electrophysiology
To gain initial insights into the mechanisms of SLC13A dysfunction,
we undertook investigations in neuronal excitability changes on the
cellular and network level, using in vitro measurements in hippocampal
brain slices. These were performed in slices from 3 Slc13a5−/− mice,
and 4 age-matched controls, as well as from 21 Wistar rats (Janvier
labs), in the latter case with and without pharmacological blockade of
the SLC13A5 transporter using PF-06761281 (2 μM; Sigma Aldrich; cf.,
Huard et al. (2016) to mimic transporter knockout functionally.
2.7.1. Brain slice preparation and maintenance
The animals were deeply anesthetized by diethyl ether inhalation
(Mallinckrodt Baker, Deventer, Netherlands) and decapitated. The
brain was quickly removed and transferred into ice-cold (4 °C) and
oxygenated (carbogen 95% O2/ 5% CO2) dissection solution containing
(in mM) 87 NaCl, 25 NaHCO3, 2.5 KCl, 1.25 NaH2PO4, 0.5 CaCl2, 7
MgCl2, 10 D-glucose and 75 sucrose adjusted to pH 7.4 with an osmo-
larity of 326–328 mosmol/l H2O. The brain was glued to a vibratome
(Integraslice 7550 MM, Campden Instruments Ltd., England) and
transversal slices of hippocampal formation (400 μm) were prepared in
chilled and oxygenated artificial cerebrospinal fluid (aCSF). ACSF was
comprised of (in mM) 124 NaCl, 26 NaHCO3, 3 KCl, 1.25 NaH2PO4, 2.5
CaCl2, 1.5 MgCl2 and 10 D-glucose adjusted to pH 7.4 with an osmo-
larity of 304–312 mosmol/l H2O. After preparation, slices were trans-
ferred into a submerged-type storage chamber for maintenance with
oxygenated aCSF and kept for 1.5 h, before transferring slices to an
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interface-type recording chamber (BSC-BU, Harvard Apparatus Inc.,
Holliston, MA, USA). During recording, slices were perfused aCSF at
32 ± 1 °C with a continual flow of 2–3 ml/min.
2.7.2. Field potential (FP) recordings of input-output curves and
epileptiform activity
FP were recorded in stratum radiatum of the CA1 subfield using
borosilicate glass pipettes (GB150-8P Science Products GmbH,
Germany) with a tip resistance of 2–3 MΩ (pulled with PIP5 puller from
HEKA Elektronik, Lambrecht, Germany) and filled with aCSF con-
taining an Ag/AgCl wire. Signals were amplified and low-pass filtered
at 1 kHz (EXT-10-2F, npi electronic GmbH, Germany). Recordings were
digitized (Micro 1401mkII, CED Ltd., Cambridge, England) and ana-
lyzed using Signal 2.16 (CED Ltd., Cambridge, England). For electrical
stimulation, Schaffer collaterals were stimulated with a bipolar pla-
tinum electrode composed of twisted insulated platinum wire (PT-2 T,
Science Products GmbH, Hofheim am Taunus, Germany). Stimulation
was controlled by a Master-8 pulse stimulator (A.M.P.I., Jerusalem,
Israel) connected to a stimulus isolator (A365, WPI Inc., Sarasota, FL,
USA), applying a paired-pulse protocol with 40 ms inter-pulse interval
(IPI) and an inter-stimulus interval (ISI) of 30 s (0.033 Hz). Baseline
stimulation strength of each slice was stepwise increased, generating an
input-output curve until saturation of amplitude of field excitatory
postsynaptic potentials (fEPSP). To induce spontaneous recurrent epi-
leptiform discharges (REDs), Mg2+ was omitted from the bath solution.
To gauge intensity of epileptiform activity, the number of REDs oc-
curring in 30 s intervals was counted. Likewise, the number of spikes /
afterdischarges was counted in all REDs during the last five minutes,
and then averaged for each slice. From these averages, the means were
obtained for Slc13a5−/− and normal tissues.
2.7.3. Intracellular recordings of active and passive membrane properties
Membrane potential recordings were obtained from CA1 pyramidal
neurons with 3 M potassium-acetate-filled (60–120 MΩ) micropipettes,
and amplified using a SEC10 amplifier (npi, Tamm, Germany).
2.8. Cerebrospinal fluid (CSF), plasma and brain tissue sampling
For proteomic and metabolomic analysis CSF, plasma and brain
tissue were sampled from the same male Slc13a5−/− and their litter-
mate controls (Slc13a5+/+) with an age of 12 weeks. Animals were
deeply anesthetized by ketamine/xylazin and blood was drawn by heart
puncture. Under stereo-microscope the skin was cut and musculus bi-
venter cervicis and musculus rectus capitis dorsalis major were pre-
pared to see the cisterna magna. Puncture of the cisterna magna was
performed with a Hamilton syringe to extract 7 to 10 μl CSF per animal
(Liu and Duff, 2008). To sample brain tissue mice were sacrificed by
cervical dislocation and brain were extracted and hippocampus and
parahippocampal cortex were prepared.
2.9. Proteome analysis of hippocampus and parahippocampal cortex
Snap frozen tissue samples were directly bead milled with a
Precellys homogenizer (Peqlab, Lutterworth, U.K.) in extraction buffer
(10 mM Tris-HCl pH 7.6 with 1% NP40, 10 mM NaCl and Complete
protease inhibitors) as described (Molin et al., 2015) and total protein
content was measured by Bradford. 10 μg total protein per sample were
digested using a modified filter-aided sample preparation (FASP)
method as described (Lepper et al., 2018). Proteomic profiling was
performed on a Q Exactive HF mass spectrometer (ThermoFisher Sci-
entific, Dreieich, Germany) operated in the data independent acquisi-
tion (DIA) mode as described (Lepper et al., 2018). Briefly, 1 μg of
peptides per sample were spiked with 1 injection unit of the HRM Ca-
libration Kit (Biognosys, Schlieren, Switzerland, #Ki-3003) for reten-
tion time indexing and automatically loaded onto the UPLC system
(Ultimate 3000, Dionex, Sunnyvale, CA) equipped with a nano trap
column (300 μm inner diameter × 5 mm, packed with Acclaim
PepMap100 C18, 5 μm, 100 Å; LC Packings, Sunnyvale, CA). After
5 min, the peptides were eluted from the trap column and separated by
reversed-phase chromatography (Acquity UPLC M-Class HSS T3
Column, 1.8 μm, 75 μm × 250 mm; Waters, Milford, MA) using a
gradient of 7–27% ACN at a flow rate of 250 nL/min over a period of
90 min, followed by a two short gradients of 27–41% ACN (15 min) and
41–85% ACN (5 min). After 5 min at 85% ACN, the gradient was set
back to 3% ACN over a period of 2 min and allowed to equilibrate for
8 min. All ACN solutions contained 0.1% FA.
The DIA method consisted of alternating MS full scans at 120000
resolution ranging from 300 to 1650 m/z followed by 37 DIA window
scans for peptide fragmentation with a variable width spanning from
300 to 1650 m/z at a resolution of 30,000. Normalized collision energy
was set to 28, and the spectra were recorded in profile type.
The DIA LC − MS/MS raw files were converted with HTRMS con-
verter and analyzed using Spectronaut (Version 11, Biognosys,
Schlieren, Switzerland) as described (91). Briefly, automatic calibration
mode was selected with precision indexed retention time (iRT) align-
ment enabled for applying the nonlinear iRT calibration strategy.
Peptides were identified by comparison to an in-house accumulated
spectral library from mouse brain samples measured on the same mass
spectrometry set-up in a data-dependent acquisition mode. Peptide
identification was filtered to satisfy a FDR of 1%. Only proteotypic
peptides were considered for protein quantification applying summed
precursor quantities based on MS2 area quantity. A match between runs
was enabled with the data filtering function set to q-value percentile
mode applying a 25% setting. This setting allows only peptide precursor
signals passing the 1% FDR threshold in at least 25% of all samples to
be considered for identification and quantification aiming to reduce
false positive identifications. Evaluation of differential protein abun-
dance between groups was performed by an unpaired Student's t-test
based on the log2 transformed sum of abundances of all unique pep-
tides per protein.
For the Pathway analysis in each region the protein abundances
were subjected to a Pathway enrichment analysis using both a licensed
(Genomatix Pathway System (GePS), Genomatix Software GmbH,
Munich, Germany) and a publically available pathway tool
(ConsensusPathDB over-representation tool (Kamburov et al., 2009).
Using both databases a list of all identified proteins was used as a
background list. Only pathways with a p value of< 0.01 and at least
two overlapping proteins were considered. Protein abundances of all
proteins found to be involved in significantly changed pathways were
visualized in a heat map. Individual fold changes for each animal were
calculated by dividing their value against the mean of the wildtype
group, these changes were log2 transformed and the resulting matrix
was visualized with the “heatmap.2” function in the “gplots” R package
(Warnes et al., 2015) using R version 3.5.1 (R Core Team, 2013).
2.10. Metabolome analysis of cerebrospinal fluid, plasma and brain
Metabolite extraction of CSF (7 μl), plasma (5 μl), and brain tissue
(10 mg) was performed using MeOH, CHCL3, and water with a ratio of
2:2:1 for plasma and CSF and 1:2:1 for tissue, respectively. Isotope
internal standards were added to CSF, plasma, and weighted preground
tissue for absolute quantification of metabolites. Plasma and CSF ex-
tracts were vortexed for 10 min at 4 °C and tissues were homogenized
using a Retsch mill for 5 min at 30 I/S. Extracts were then centrifuged at
16,000 ×g for 5 min at 4 °C and the upper aqueous phase was eva-
porated and used for metabolite analysis.
Metabolite derivatization and GC–MS analysis was performed as
previously described (Cordes and Metallo, 2019). In short, metabolite
derivatization was performed using a Gerstel MPS with 15 μl of 2% (w/
v) methoxyamine hydrochloride (Thermo Scientific) in pyridine (in-
cubated for 60 min at 45 °C) and 15 μl N-tertbutyldimethylsilyl-N-me-
thyltrifluoroacetamide (MTBSTFA) with 1% tert-
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butyldimethylchlorosilane (Regis Technologies) (incubated further for
30 min at 45 °C). Derivatized samples were analyzed by using a DB-
35MS column (30 m × 0.25 i.d. x 0.25 μm) installed in an Agilent
7890B gas chromatograph (GC) interfaced with an Agilent 5977A mass
spectrometer (MS) operating under electron impact ionization at 70 eV.
The MS source was held at 230 °C, the quadrupole at 150 °C and helium
was used as carrier gas. For MTBSTFA derivatized samples, the GC oven
was held at 100 °C for 2 min, increased to 300 °C at 10 °C/min, and held
at 325 °C for 3 min. For absolute quantification of citrate and amino
acids, a 13C, 15N labeled amino-acid mixture (Cambridge isotope la-
boratories, Cat. No MSK-A2–1.2) and [2,4-13C]citrate were used as an
internal standards. Details on specific fragments are provided elsewhere
(Cordes and Metallo, 2019).
2.11. Statistical analysis
Sample size was set based on power analysis calculations using
GPower to provide power greater than 0.80 for α = 0.05 for most
experiments. Except otherwise indicated, all studies were blinded at the
level of data analysis. Data from the Morris water maze were analyzed
by two-way ANOVA with posthoc comparisons by Tukey's multiple
comparisons test. For comparison of frequencies in a 2 × 2 table,
Barnard's unconditional test (Barnard, 1947) was used, because this test
preserves the significance level and generally is more powerful than
Fisher's exact test for moderate to small samples (Lydersen et al., 2009).
As with most types of epilepsy in humans, spontaneous recurrent
seizures in rodent models are typically infrequent with seizure fre-
quencies of often only 1–2/week and variable inter-seizure intervals
(Löscher, 2017). Appropriate statistical models for rare events are based
on Poisson random effects models (Johnson et al., 2005; Cai et al.,
2010), which was applied here. For analyzing differences in seizure
frequency between groups, a Generalized Linear Model with a Poisson
error and a log-link was used. Due to an extended overdispersion, a
quasi-likelihood approach using a Quasi-Poisson model to account for
this was adopted as additional model. These models were performed
with R (version 3.4.0; R Core Team (2013)).
Electrophysiological experiments were analyzed using ANOVA to
compare passive intracellular properties, and Mann-Whitney Rank Sum
Test for comparison of fEPSP slopes. The temporal development of RED-
frequency during 0-Mg2+ washout was compared with Kolmogorov-
Smirnov-Test. These analyses were performed with SigmaStat 3.5.
All other statistical analyses were performed with the Prism 8
software from GraphPad (La Jolla, CA, USA). All tests were used two-
sided; a p ≤ .05 was considered statistically significant.
Fig. 1. Representative intrahippocampal EEG recordings in Slc13a5+/+ and Slc13a5−/−mice. The code number of individual mice is indicated above each recording
and refers to the numbers given in Table 1, Table S5 and text. (A) Normal baseline activity without any paroxysmal alterations in a Slc13a5+/+ mouse. Higher
magnification showed the typical theta rhythm (rhythmic slow wave activity, 6–9 Hz) occurring in hippocampal recordings of mice. The baseline activity did not
differ in Slc13a5−/− mice (not shown). (B) Isolated spikes in the hippocampal EEG of a Slc13a5+/+ mouse. (C) Paroxysmal EEG activity characterized by an
irregular, high-amplitude cluster of spikes, associated by myoclonic twitches in a Slc13a5+/+ mouse. (D) Isolated spikes in the hippocampal EEG of a Slc13a5−/−
mouse. (E) Paroxysmal high-amplitude run of spikes, during which the Slc13a5−/− mouse exhibited behavioral arrest, resembling limbic (focal nonconvulsive)
seizure. (F) Paroxysmal EEG activity, characterized by polymorphic high-amplitude spikes and sharp waves, during which the mouse started to twitch, then stretched
and flipped over, resembling a generalized convulsive seizure. (G) Paroxysmal EEG activity, lasting about 60 s and characterized by irregular spiking, with low- and
high-amplitude spikes, during which behavioral arrest could be observed in a Slc13a5−/− mouse. (H) Paroxysmal EEG activity characterized by irregular, low- and
high-amplitude run of spikes, which were associated by myoclonic twitches in a Slc13a5−/−mouse. Please note that 30 s of EEG are shown for each animal here. Also
note the different amplitudes (in mV) of the recordings. The same EEG recordings with higher time-resolution (but only 10 s duration) are shown in Fig. S1.
Furthermore, representative examples of the electroclinical seizures recorded in Slc13a5+/+ and Slc13a5−/− mice are shown in movies S1-S4.
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3. Results
3.1. Deletion of citrate transporter SLC13A5 leads to epileptic seizures but
no obvious behavioral or histological abnormalities in mice
As described in the introduction, patients with homozygous or
compound heterozygous loss-of-function mutations in the citrate
transporter SLC13A5 suffer from severe seizure activity and other ac-
companying clinical signs of epilepsy and encephalopathy, whereas
heterozygous carriers are not affected. However, in studies focusing on
e.g. liver function (Birkenfeld et al., 2011), our mouse model did not
show any obvious neurological alterations. Because of the recent clin-
ical findings regarding SLC13A5-associated human epilepsy, we per-
formed a more detailed neurological investigation in Slc13a5−/− mice.
For continuous (24/7) video-EEG monitoring, Slc13a5−/− mice and
littermate heterozygote (Slc13a5+/−) mice as well as littermate con-
trols (Slc13a5+/+) of both sex were used, starting at about 7 weeks of
age. Body weight of the male and female Slc13a5−/− mice used in our
experiments was significantly (15–20%) lower compared to controls,
confirming previous data (Table S2) (Birkenfeld et al., 2011). The dif-
ference in body weight has been explained by a reduction in body size
without changes in body composition in young normally fed mice
(Birkenfeld et al., 2011).
A total of 2688 h of video-EEG recordings were visually analyzed for
occurrence of spikes, electrographic or electroclinical seizures and
other abnormal epileptiform activity by experienced observers. In case
of any abnormal EEG activity, which was recorded by a depth electrode
in the hippocampus, the concomitant video was viewed for behavioral
alterations. Based on commonly used definition of seizures (Fisher
et al., 2014), an electroclinical seizure was defined as paroxysmal EEG
alteration associated by abnormal convulsive or nonconvulsive beha-
vioral alterations with a duration of at least 10 s.
“Normal” baseline EEG activity did not differ between Slc13a5+/+
and Slc13a5−/− mice (Fig. 1A). In both groups, the hippocampal EEG
was characterized by typical theta oscillations (6–9 Hz). See Fig. S1 for
records with higher time-resolution.
However, EEG spikes or spike clusters were noted in 5 of 8
Slc13a5+/+ and 7 of 8 Slc13a5−/− mice (Fig. 1B and D) at irregular
intervals. Such activity may occur in “normal” control mice with depth
electrodes, possibly as a result of the damage produced by the electrode
(Twele et al., 2017). Abnormal, epileptic EEG activity was detected in 1
of 8 Slc13a5+/+ and 4 of 8 Slc13a5−/− mice (p = .1363; Fig. 1;
Table 1; Fig. S1). In the Slc13a5+/+ mouse #0119 (Fig. 1C), this EEG
activity was observed twice on one day during the 2 week-recording
period. The abnormal EEG activity was characterized by an irregular,
high-amplitude spike cluster lasting about 15 s. This was associated
with myoclonic twitches and jumping during running through the cage
(Movie S1). In the 4 Slc13a5−/− mice with epileptic EEG activity, EEG
abnormalities and associated clinical alterations were as follows: Mouse
#0110 (Fig. 1E) exhibited six periods of paroxysmal EEG activity,
lasting about 20 s each and characterized by high-amplitude run of
spikes, during which the mouse showed either behavioral arrest or
myoclonic activity (Table 1; Movie S2). Mouse #0114 (Fig. 1F) ex-
hibited two periods of paroxysmal EEG activity, lasting about 20 s and
characterized by polymorphic high-amplitude spikes and sharp waves,
during which the mouse started to twitch, then stretched and flipped
over, resembling a generalized convulsive (stage 5) seizure (Movie S3).
Mouse #0139 (Fig. 1G) exhibited three periods of paroxysmal EEG
activity, lasting about 60 s and characterized by irregular spiking, with
low- and high-amplitude spikes, during which the mouse exhibited
behavioral arrest, resembling a limbic (focal nonconvulsive) seizure (as
also exhibited by mouse #0110 in Movie S2). Mouse #0165 (Fig. 1H)
exhibited one period of paroxysmal EEG activity, lasting about 30 s and
characterized by an irregular, low- and high-amplitude run of spikes,
which was associated by myoclonic twitches (Movie S4).
Overall, only two periods of seizure-like epileptic EEG activities
were observed in one Slc13a5+/+ mice compared to 12 such activities
in four Slc13a5−/− mice, including two convulsive (stage 5) seizures in
one Slc13a5−/− mouse (Table 1). The severity of the observed seizures
and cumulative seizure severities are shown in Table 1. The circadian
distribution of the paroxysmal EEG activities and seizures varied. In-
terictal spikes as shown in Fig. 1D were observed in-between the epi-
leptic EEG events. Statistical analysis of the seizure frequencies in
Slc13a5−/− vs. Slc13a5+/+ mice by a Generalized Linear Model with a
Poisson error and a log-link resulted in a significant difference between
groups (p = .0190). On the original scale this was equivalent to an
incident rate of 6.00 (95% CI, 1.64 to 38.56). These effects were also
recognized within the Quasi-Poisson approach where Slc13a5−/− mice
compared to wildtype mice are expected to have a rate 6.00 times
greater for the number of seizures, but due to a restricted sensitivity of
this model with no statistical significance (p = .162).
To test if Slc13a5 deficiency in mice results in altered seizure sus-
ceptibility, seizure threshold was determined by the timed i.v. PTZ in-
fusion test. PTZ seizure thresholds did not significantly differ between
the different genotypes (Table S3). The only significant difference was
that the maximum seizure severity was higher in female Slc13a5−/−
mice (5.5 ± 1.6) vs. female Slc13a5+/+ mice (3.4 ± 0.5; p= .0163).
The number of animals which did not survive the seizures did not differ
significantly (Table S3).
Since patients with SLC13A5 mutations have developmental delays
and impairments in motor function (Thevenon et al., 2014; Klotz et al.,
2016; Alhakeem et al., 2018), a set of behavioral tests including Irwin
Table 1
Results of the video-EEG monitoring over 2 weeks in Slc13a5+/+ and Slc13a5−/− mice. Experiments were started at 7 weeks of age.
Slc13a5+/+(n = 8) Slc13a5−/−(n = 8)
Mouse #
and sex
Seizures Mouse #
and sex
Seizures
Incidence of
seizures
Number of
seizures per
mouse
Seizure
severity
(score)
Cumulative seizure
severity (score)
Incidence of
seizures
Number of
seizures per
mouse*
Seizure
severity
(score)
Cumulative seizure
severity (score)
99 ♂ − 0 0 0 107 ♀ − 0 0 0
108 ♀ − 0 0 0 110 ♀ + 6 4 × 1, 2 × 2 8
119 ♀ + 2 2 × 2 4 114 ♀ + 2 2 × 5 10
120 ♀ − 0 0 0 129 ♀ − 0 0 0
123 ♂ − 0 0 0 139 ♂ + 3 3 × 1 3
142 ♂ − 0 0 0 141 ♂ − 0 0 0
163 ♂ − 0 0 0 154 ♂ − 0 0 0
167 ♂ − 0 0 0 165 ♂ + 1 1 × 2 2
Sum 1/8 4 Sum 4/8 23
*Significantly different from Slc13a5+/+ mice (p = .0190).
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screen and rotarod, Morris water maze, and novelty-induced hypo-
phagia test were performed in the Slc13a5−/− mice and controls. In
none of the tests obvious alterations in behavior were observed in
Slc13a5−/− mice (Fig. 2, Table S4). Rotarod performance was com-
parable for both genotypes and sexes with all but two female Slc13a5−/
− mice passing the test after one training session. The two female
Slc13a5−/− mice failed to walk on the turning rod (6 rpm) for 60 s at
the second day of testing.
In the Morris water maze a characteristic learning curve was evident
in both genotypes (Fig. 2A). The average escape latency significantly
decreased over time without a significant group difference between
Slc13a5−/− mice and Slc13a5+/+ mice. In the spatial probe on the last
day of testing, neither Slc13a5+/+ nor Slc13a5−/− spent significantly
more time at the former platform position compared to other quadrants
of the water tank (Fig. 2B). No sex differences were observed, so data
from both sexes were averaged. Finally the novelty-induced hypophagia
test did not reveal any differences between Slc13a5+/+ and Slc13a5−/
− mice for the assessed parameters such as total distance moved, ve-
locity, latency to first entry into the center (where the snack was
placed), time spent in each zone (center/inner/outer zone), rearing and
grooming behavior (Table S4).
Analysis of brain histology by thionin staining and myelin staining
by luxol fast blue (LFB) did not show any obvious differences between
Slc13a5+/+ and Slc13a5−/− mice (Fig. 3). Most of the mice of both
genotypes exhibited hydrocephalic brain alterations, characterized by
enlargement of the lateral and third ventricles and the aqueductus
mesencephali (for details see Table S5). This was not associated with
any obvious neurologic or behavioral alterations in the Slc13a5+/+
mice (except the two seizures observed in mouse #119). A comparison
of the hydrocephalic brain alterations with occurrence of seizures in
Slc13a5+/+ and Slc13a5−/− mice did not indicate any obvious re-
lationship (Table S5).
As to be expected, the hippocampal electrode implantation led to
focal neurodegeneration or tissue destruction at the electrode im-
plantation site, but no marked signs of focal inflammation or abscess
formation were observed. No significant differences were seen between
the knockout and wildtype mice at the electrode implantation site in
the hippocampus apart from the morphological findings listed in Table
S5. We therefore found no obvious histological changes that may ex-
plain the epileptic activity observed in the wild-type mouse.
Furthermore, no differences were seen between Slc13a5−/− that did or
did not exhibit epileptic seizures.
3.2. Both deletion and pharmacological blockade of citrate transporter
SLC13A5 increase hippocampal CA1 network excitability
To explore the pathomechanism of the epileptic phenotype de-
scribed in vivo, we investigated hippocampal synaptic/network excit-
ability changes in both Slc13a5−/− tissue, and in normal tissue
blocking SLC13A5 pharmacologically. For these experiments we used
the in vitro hippocampal slice preparation, which allows for dosage-
controlled drug application without variability being introduced by
metabolic or blood-brain barrier issues.
First, we were interested in hippocampal network excitability and
epileptogenicity. We therefore tested the propensity of Slc13a5−/−
hippocampal slices to generate epileptiform activity in the acute 0-
Mg2+ in vitro epilepsy model, which induces recurrent epileptiform
discharges (REDs) (Müller et al., 2013; Brehme et al., 2014). Compared
to control slices, there was no difference in the frequency of these
events (Fig. 4A), at first sight suggesting no network excitability
change. However, the latency to first REDs was consistently ~10 min
shorter in Slc13a5−/− brain tissue than in control (Fig. 4A, p < .001),
testifying that with dysfunctional transporter, the tissue becomes more
readily excitable during Mg2+ washout phase. More importantly, al-
though the frequency of REDs was not increased, their morphology
clearly was different, since in Slc13a5−/− brain tissue REDs manifested
polyspikes/afterdischarges (9.87 ± 1.85 spikes; Fig. 4B insets) in 10/
12 slices, while in control tissue, only 8/16 slices did so, with sig-
nificantly less polyspikes/afterdischarges (4.21 ± 1.23 spikes;
P < .05; Fig. 4B insets). Since such polyspikes / afterdischarges are
deemed to be a sign of epileptogenicity (Smith and Dudek, 2001;
Wozny et al., 2005), this again indicates that Slc13a5−/− brain tissue is
intrinsically more epileptogenic.
We next wanted to explore whether this increased excitability in
Slc13a5−/− mice is also evident in Mg2+-containing ACSF. To test this,
we induced field excitatory postsynaptic potentials (fEPSP) in CA1 in
normal, i.e. Mg2+-containing ACSF, using afferent Schaffer collateral
stimulation at increasing stimulation strengths. As can be seen in Fig. 4
C and D, under these conditions, there was no functional difference
between Slc13a5−/− and normal tissue.
Since persistent (constitutive) knockout of a transporter can in
Fig. 2. Learning of platform location by Slc13a5+/+ and Slc13a5−/− in the
Morris water maze test. “A” shows the mean time to reach the hidden platform
(“escape latency”) during the 10 days of water maze testing (acquisition
period). Each day, the mice were subjected to four 1-min trials in the maze, and
the data of the four trials per day were averaged for each mouse. Both geno-
types showed significant learning over the period of the trials. Significant dif-
ferences to day 1 in Slc13a5+/+ mice are indicated by asterisk (*p < .05;
**p < .01), while significant differences to day 1 in Slc13a5−/− mice are
indicated by the hash sign (#p < .05; ##p < .01). “B” shows the results of the
probe trial (day 10, 4th trial), in which the platform was removed and the
crossings of the former platform position during a single trial over 60 s were
recorded. Neither Slc13a5+/+ nor Slc13a5−/− spent significantly more time at
the former platform position compared to other quadrants of the water tank. In
both graphs, data are presented as means± SEM of 10 mice per genotype.
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principle activate adaptive changes during development, the above-
described excitability increases in Slc13a5−/− tissue could be due to
such adaptive plasticity. Thus, to confirm the involvement of SLC13A5
transporter in the control of network excitability in a general way, we
investigated the effects of pharmacological SLC13A5 transporter block
using the specific antagonist PF-06761281 (2 μm) in normal rodent
(now rat) hippocampal tissue in a set of experiments mirroring the
above, such that adaptive mechanisms due to knockout of the gene and
species-specific effects can be ruled out. With respect to PF-06761281,
it should be noted that this compound is a dicarboxylate molecule
mimicking citrate and potentially having chelating properties as well
(Willmes and Birkenfeld, 2013). Therefore, an unspecific effect by the
dicarboxylate cannot be ruled out. Additionally, PF-06761281 is also
inhibiting astrocyte specific SLC13A3 transporter to a lesser extent,
potentially influencing the experiments.
Gauging the severity of hippocampal REDs, we could recapitulate
the epileptogenic phenotype also under pharmacological blockade of
the transporter, albeit qualitatively different than in Slc13a5−/− mouse
tissue. Rather than generating more polyspikes/afterdicharges or
showing differences in the latency of RED emergence, the frequency of
REDs was significantly increased with functionally blocked SLC13A5
(Fig. 4 E,F, p < .001), demonstrating that impeded transporter func-
tion also using an alternative to knockout is instrumental in shaping
network excitability, although in a slightly different fashion.
Analyzing excitatory synaptic responsiveness, we found that under
transporter blockade, even normal fEPSPs in CA1 under non-epilepto-
genic conditions were increased. As can be seen in Fig. 4 G,H, the re-
sulting input-output curve under citrate transporter block was increased
significantly (p = .012–0.032), indicating that under these conditions
also synaptic responsiveness was augmented, too.
As the above hyperexcitability phenomenon could in principle be
due to changes in intrinsic or synaptic excitability, we analyzed CA1-
neuronal passive and firing behavior, using sharp-microelectrode in-
tracellular recordings (Table S6). Neither input resistance nor time
constant were different between the two groups, nor was firing beha-
vior (firing input-output curves not different between the two groups;
data not shown). In addition, we tested for differences of intrinsic
currents modulating excitability of neurons, i.e., HCN channel-depen-
dent voltage sags at hyperpolarizing current injections, or calcium ac-
tivated potassium current-dependent after-hyperpolarizations at
depolarizing current injections. Neither of the two was different be-
tween neurons with and without SLC13A5 block, ruling out that the
transporter has any major impact on intrinsic neuronal behavior.
3.3. Proteome analysis indicates alterations in neurotransmitters,
extracellular matrix organization and lipid metabolism in the brain of
SLC13A5 deficient mice
In order to detect potential changes in protein abundance in
Slc13a5−/− mice, a quantitative proteomic analysis was performed on
hippocampus and parahippocampal cortex tissue using five wildtype
and five Slc13a5−/− mice. In the hippocampus 5.4% (286 out of 5249)
and in the parahippocampal cortex 1.5% (77 out of 5249) of identified
proteins showed a significant difference in abundance levels.
In order to obtain information about the regulation of mechan-
istically linked groups of proteins, we subjected the datasets of differ-
entially abundant proteins to pathway enrichment analysis using two
databases, ConsensusPathDB and Genomatix. A total of 30
(ConsensusPathDB) and 3 (Genomatix) regulated pathways were iden-
tified in the hippocampus (Table S7A, B). In the parahippocampal
cortex, regulation of 59 (ConsensusPathDB) and 9 (Genomatix) path-
ways was demonstrated (Table S8A, B). With regard to the total number
of regulated pathways, it needs to be considered that several of these
regulated pathways share the same subset of proteins. Expression levels
of all proteins involved in regulated pathways are illustrated in Fig. 5.
In the hippocampus, regulated protein groups that can be directly
linked to neuronal activity and its regulation comprised GABA- (e.g.
GABA shunt, GABA synthesis, release, reuptake and degradation of GABA)
and serotonin-related pathways (metabolism of serotonin, serotonin
clearance from the synaptic cleft, and serotonin degradation). In these
pathways, proteins involved in GABA trafficking (STX1A and DNAJC5)
and metabolism (ALDH5A1 and ABAT) exhibited significantly lower
abundance levels in Slc13a5−/− mice. Abundance of glutamate dec-
arboxylase 65 (GAD65; encoded by GAD2), a catalyst for the production
of GABA, showed significantly higher levels in knockout mice. The
proteins involved in serotonin metabolism and degradation (MAOA and
ALDH2) exhibited significantly decreased abundance levels in
Slc13a5−/− mice.
Analysis of protein expression patterns in the parahippocampal
cortex did not reveal significantly over- or underrepresented pathways,
Fig. 3. Representative photomicrographs of
thionin-stained (left) and luxol fast blue-
stained (right) brain sections of a Slc13a5+/
+ and a Slc13a5−/− mouse. No neuronal
abnormalities in hippocampal formation
and parahippocampal areas or changes of
neuronal myelination of Slc13a5−/− were
observed. Note the ventricle enlargement in
both mouse genotypes (see Table S5 for
details). Cc = corpus callosum;
CA1 = cornu ammonis 1. Scale bar
left = 200 μm. Scale bar right = 100 μm.
(For interpretation of the references to color
in this figure legend, the reader is referred
to the web version of this article.)
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which are directly linked with neuronal activity. However, significant
group differences became evident in the abundance of proteins involved
in extracellular matrix organization and immune response (in the il 3
signaling pathway). In these pathways, protein tyrosine phosphatase,
non-receptor type 6 (PTPN6) exhibited the strongest regulation with a
pronounced reduction as a consequence of the Slc13a5 genetic defi-
ciency.
Further regulated pathways do not seem to be directly related to an
epileptic phenotype of the Slc13a5−/−mice. The significant differential
expression of several pathways in the hippocampus indicates differ-
ences in metabolic functioning (respiratory electron transport, complex I
biogenesis and oxidative phosphorylation pathways). The respective pro-
teins proved to be dysregulated with either lowered or increased
abundance of mammalian respiratory complex I proteins in Slc13a5−/−
mice. In the parahippocampal cortex, significant differences in lipid
metabolism pathways (lipoprotein metabolism, HDL-mediated lipid trans-
port and lipid digestion, mobilization, and transport) were identified with
an increased abundance of low density lipoprotein receptor (LDLR) and
apolipoprotein A1 (APOA1) in Slc13a5−/− mice.
3.4. Deletion of the citrate transporter Slc13a5 leads to altered citrate
concentrations in cerebrospinal fluid (CSF) and parahippocampal cortex
Next, we performed metabolomic analyses to examine whether the
deletion of the citrate transporter SLC13A5 leads to changes in the
composition of organic acids and amino acids in plasma, CSF, and brain
Fig. 4. Effect of the Slc13a5 knockout (A-D)
and of the SLC13A5 inhibitor PF-06761281
(2 μM) (E-H) on hippocampal network ac-
tivity and synaptic transmission of Schaffer
collateral-CA1 pyramidal cell synapses. (A)
Epileptiform discharges recorded in the
stratum radiatum of CA1-region were
monitored during perfusion with Mg2+-free
ACSF. Note the left-shift of discharge onset
of spontaneous epileptiform discharges in
Slc13a5−/− mouse slices (open circles), as
compared to control mouse slices (closed
circles). Asterisks: Significant shift,
p < .001, Kolmogorov-Smirnov-Test. (B)
Representative sample traces of REDs illus-
trating the increased incidence of poly-
spikes / afterdischarges in knockout tissue
(see insets with single discharges enlarged
from traces) 60 min after of removal of
Mg2+. (C) Input-output curves representing
fEPSP slope in response to increasing sti-
mulus input in Slc13a5−/− mouse slices
(open circles), as compared to control
mouse slices (closed circles). (D)
Representative traces illustrated by over-
laying each fEPSP to stimulus from 0 to
300 μA. (E) Epileptiform discharges re-
corded in the stratum radiatum of CA1-re-
gion in rat slices were monitored during
perfusion with Mg2+-free ACSF. Note the
significant increase of spontaneous epi-
leptiform discharges in the presence of PF-
06761281 (open circles) compared to con-
trol experiments without PF-06761281
(closed circles) (p < .001, Kolmogorov-
Smirnov-Test). (F) Representative sample
trace illustrating the occurrence of sponta-
neous epileptiform activity 60 min after
removal of Mg2+. (G) Input-output curves
representing fEPSP slope in response to in-
creasing stimulus input with (open circles)
and without PF-06761281 (closed circles).
(H) Representative traces illustrated by
overlaying each fEPSP to stimulus from 0 to
300 μA.
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tissue. Mice were fasted for 4 h in the morning. Then, plasma, CSF and
tissues from the parahippocampal cortex and hippocampus were ob-
tained as described in the Methods section. Samples were analyzed with
gas chromatography–mass spectrometry (GC–MS). In plasma, we did
not observe any significant change in organic acid levels in Slc13a5
knockout and wildtype mice (Fig. 6A and Fig. S2 A-C). Therefore, po-
tential changes in CSF or brain might not be explained by systemic
changes. In CSF of Slc13a5−/− mice, citrate levels were significantly
increased (Fig. 6B) compared to Slc13a5+/+mice. In apparent contrast,
citrate levels were significantly decreased in parahippocampal cortex in
Slc13a5−/− mice (Fig. 6C). Of note, citrate was markedly lower in CSF
than in plasma (Fig. 5A, B) of both, wildtype and knockout mice. Lac-
tate and succinate levels were reduced in CSF of Slc13a5−/− mice
compared to Slc13a5+/+ mice (Fig. 6D, E). The amino acids glutamate
and aspartate were increased by 34 ± 5% and 29 ± 3%, respectively,
in the CSF of Slc13a5−/− mice (Fig. 6F, S1). Other amino acids did not
differ between Slc13a5−/− and Slc13a5+/+ mice, neither in CSF nor in
plasma (Figs. S2 and S3). Beside decreased citrate levels in para-
hippocampal cortex, no other major changes were observed in the
tissue metabolites including GABA and N-acetylaspartate (NAA; Figs. S4
– S6).
4. Discussion
The main findings of the present study are summarized in Fig. 7.
Using continuous (24/7) video-EEG monitoring as well as ex vivo
electrophysiological recordings, our data demonstrate that deletion of
Slc13a5 in a mouse model leads to increased neuronal excitability re-
sulting in increased propensity for epileptic seizures, thus indicating a
good face validity of the mouse model. However, during the two weeks
of video/EEG monitoring, epileptic seizures were only observed in 50%
of mice with deleted Slc13a5, which may either indicate a very low
seizure frequency in the other 50% of mice or incomplete penetrance of
the deletion in the affected animals. Penetrance refers to the likelihood
that a clinical condition (or phenotype) will occur when a particular
genotype is present. A condition is said to show incomplete penetrance
when some individuals who carry the pathogenic variant express the
associated trait while others do not, which is also known from other
genetic rodent models of epilepsy (Kurtz et al., 2001; Mulley and
Mefford, 2011; Italiano et al., 2016; Liu et al., 2019). The penetrance in
humans with SLC13A5 loss-of-function mutation is unknown but none
of the individuals with heterozygous mutations show any epileptic
phenotypes (Thevenon et al., 2014; Hardies et al., 2015; Klotz et al.,
2016; Schossig et al., 2017; Alhakeem et al., 2018).
As reported in patients with SLC13A5 mutations (Hardies et al.,
2015; Klotz et al., 2016), seizure types in Slc13a5−/−mice ranged from
myoclonic and focal (nonconvulsive), which was observed in the ma-
jority of affected mice, to generalized convulsive seizures. Clinical sei-
zures were associated with paroxysmal EEG alterations, which were
recorded by depth electrodes from the hippocampus. Unexpectedly,
paroxysmal EEG alterations associated with myoclonic twitches and
jumping were also observed in one Slc13a5+/+ mouse, but overall
seizure frequency was significantly higher in the Slc13a5−/− mice.
Furthermore, generalized convulsive seizures were only observed in a
knockout mouse. Interestingly, the behavioral arrest (or “freezing”)
observed in some of the mutant mice during paroxysmal EEG activity is
a typical limbic (or focal) seizure activity also observed in the in-
trahippocampal kainate model in mice (Riban et al., 2002). Such limbic
seizure activity was not observed in Slc13a5+/+ controls, indicating
hippocampal abnormalities in the Slc13a5−/− mice. It is important to
note that without continuous video-EEG monitoring, most epileptic
seizures in Slc13a5−/− mice would have been overseen, because gen-
eralized convulsive seizures occurred so rarely, and the more frequent
limbic or myoclonic seizures are difficult to detect without continuous
EEG recording.
In the present study, we recorded seizures by depth electrodes from
the hippocampus in vivo. However, this does not necessarily imply that
these seizures originated in the hippocampus. Instead, the metabolomic
data on parahippocampal cortex vs. hippocampus demonstrate that the
Fig. 5. Expression analysis of proteins for the hippocampus and para-
hippocampal cortex of 5 wildtype (WT; Slc13a5+/+) and 5 knockout (KO;
Slc13a5−/−) mice are shown. For hierarchical row clustering protein data was
log2 transformed. Red cell color indicates an upregulation, blue cell color a
down-regulation. The respective color code is given above the heat map. (For
interpretation of the references to color in this figure legend, the reader is re-
ferred to the web version of this article.)
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decrease in citrate levels in Slc13a5-knockout mice was restricted to the
parahippocampal cortex, which may thus constitute a region of seizure
onset. Thus by using hippocampal depth electrodes for seizure detec-
tion, part of the seizures may have been missed. The parahippocampal
region, which surrounds the hippocampus and encompasses a large
portion of the medial temporal lobe, including the piriform, perirhinal,
and entorhinal cortices, is important in contributing to limbic seizure
initiation and epileptogenesis; seizures generated in the para-
hippocampal cortex propagate to the hippocampus, altering the excit-
ability of hippocampal neurons as seen here (Löscher and Ebert, 1996;
Nadel, 2000; Scharfman, 2000; McIntyre and Gilby, 2008).
The present electrophysiological experiments in hippocampal slices
suggest that network excitability is significantly increased when the
function of the SLC13A5 transporter is infringed. This corroborates the
increased seizure susceptibility as shown in the in vivo experiments in
Slc13a5−/− mice, and further confirms that this is not species specific,
since transporter block in rat tissue also induces increased excitability.
The hyperexcitability signs are likely due to synaptic, rather than in-
trinsic neuronal property changes, as the latter are not influenced by
transporter dysfunction. Indeed, one may speculate that at least in the
knockout tissue, NMDA-receptor-mediated transmission is enhanced, as
this has been linked to afterdischarge-generation by other groups pre-
viously (Behr et al., 2001). A possible explanation for differences be-
tween pharmacological inhibition of SLC13A5 and Slc13a5 knock-out
observed here (see Results) would be compensatory mechanisms during
development of the knock-out mice. Irrespective of this, the molecular
mechanisms underlying the hyperexcitability change seen in the
hippocampal slices of both Slc13a5−/− mice and normal rats could
include NMDA or AMPA receptor enhancement (Westergaard et al.,
2017; Kalappa and Tzounopoulos, 2017) or GABAergic (disinhibitory)
mechanisms (Wilkins and Smart, 2002), as any of these receptors has
been shown to be modulated by Zn2+, which could in effect be in-
creasingly chelated by ambient citrate (estimated to be around 2.1 mM
in hippocampal slices [McDougal Jr. et al., 1997]) due to citrate
transporter block (Westergaard et al., 2017).
When determining individual seizure threshold by PTZ infusion,
female Slc13a5−/− mice exhibited significantly higher seizure severity
than female controls, which was not observed in male Slc13a5−/−
mice, thus indicating a sex difference in the consequences of the
Slc13a5 knockout in mice. This observation seems to be confirmed in
the clinical setting (personal communication, Dr. Brenda Porter,
Department of Neurology, Stanford University School of Medicine,
U.S.), but detailed studies are needed in patients to formally confirm
the notion of a higher seizure severity in female subjects.
Other than occurrence of spontaneous seizures or alterations in
seizure threshold, Slc13a5−/− mice did not show any obvious beha-
vioral or cognitive abnormalities in a battery of behavioral tests. In
affected humans, SLC13A5-associated epilepsy is accompanied with
developmental delay, slow progression of motor function, variable
combinations and degrees of ataxia, choreoathetosis and spasticity, and
significant impairment in language and speech development (Bhutia
et al., 2017). Whereas the developmental delay may be reflected by the
lower body weight gain observed in Slc13a5−/−mice, slow progression
of motor function or ataxia were not noted in these animals. Phenotypic
Fig. 6. Citrate, TCA-cycle intermediates and amino acid analysis of CSF and plasma from Slc13a5+/+ (closed circles) and Slc13a5−/− (open circles) were analyzed
by GC–MS. (A) Citrate levels are not changed in plasma of Slc13a5−/− mice, whereas they are increased in CSF (B). (C) Citrate in parahippocampal cortex (PHC) is
significantly decreased in Slc13a5−/− mice, but not changed in hippocampus (HC). (D) Succinate as well as lactate (E) are decreased in CSF of Slc13a5−/− mice,
whereas aspartate and glutamate are increased in CSF (F). Data are shown as mean ± SE;M; *p < .05; **p < .01.
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differences between affected mice and humans may relate to physio-
logically relevant differences in kinetic features between the human
and rodent transporters in that the Michaelis constant for the trans-
porter to transport citrate is ~20 μM in mice, whereas the corre-
sponding value for the human is at least 30-fold higher (Birkenfeld
et al., 2011; von Loeffelholz et al., 2017; Willmes et al., 2018). How-
ever, it cannot be excluded that other mechanisms, unrelated to
SLC13A5, further contribute to the human phenotype.
Histological examination of hippocampus and parahippocampal
areas did not disclose any neuronal differences between Slc13a5−/−
mice and Slc13a5+/+ controls. However, both mouse genotypes ex-
hibited hydrocephalic brain alterations, which were not associated with
any obvious neurologic or behavioral abnormalities in Slc13a5+/+
controls (except the two seizures observed in mouse #119). However,
we cannot exclude that hydrocephalus in Slc13a5−/− mice contributed
to the phenotypic consequences of Slc13a5 deletion, although hydro-
cephalus is not commonly recognized as a cause of seizures (Sato et al.,
2001). Congenital hydrocephalus is a relatively frequent observation in
genetically engineered mice, particularly when using C57BL back-
ground strains, and is often due to dysfunction of motile cilia on
ependymal cells (Vogel et al., 2012). To our knowledge, it is not known
whether SLC13A5 mutations in patients are associated with consistent
structural brain alterations. Furthermore, as yet no conclusive MRI or
other imaging data from affected homozygous patients, heterozygous
carriers (who have no noticeable phenotype) and their parents are
available. Thevenon et al. (2014) described that brain imaging was not
conclusive in seven patients from two families. Klotz et al. (2016) re-
ported that in a group of nine epilepsy patients with SLC13A5 muta-
tions, MRI was normal in six, while one patient exhibited focal frontal
lobe thickening, one patient hyperintense foci in parietal white matter,
and one patient focal loss of gray matter, respectively. In another study
in eight patients with homozygous or compound heterozygous muta-
tions in the SLC13A5 gene, six out of seven infants with a neonatal MRI
had a characteristic MRI pattern, with punctate white matter lesions,
which were no longer visible at the age of 6 months, but led to gliotic
scarring visible on MRI at the age of 18 months (Weeke et al., 2017).
Hardies et al. (2015) reported MRI findings in two affected siblings,
indicating periventricular leukomalacia-like abnormalities, which are
known to result in hydrocephalus (Deng et al., 2008).
Virtually nothing is known about the molecular basis for the de-
velopment of epilepsy in children with loss-of-function mutations in
SLC13A5 except that the association between SLC13A5 mutations and
epilepsy may indicate an obligatory neuronal function for the trans-
porter in the brain (Bhutia et al., 2017). Based on theoretical grounds,
Bhutia et al. (2017) have proposed several potential mechanisms (cf.,
Fig. 7), including the “neuronal cytoplasmatic citrate deficit hypoth-
esis”, the “interneuron energy hypothesis”, and the “zinc chelation
hypothesis”. Furthermore, SLC13A5 defects might interfere with neu-
ronal myelination (Bhutia et al., 2017). These hypotheses were ad-
dressed in our experiments in Slc13a5−/− mice.
In the brain, citrate is released from astrocytes to the extracellular
space and is normally transported into the cytoplasm of neurons
through the action of SLC13A5 (Sonnewald et al., 1991; Westergaard
et al., 1995; Westergaard et al., 2017). Our metabolomic data from
GC–MS analysis of plasma, CSF and brain tissue show that deletion of
SLC13A5 leads to increased citrate levels in CSF and decreased citrate
levels in parahippocampal cortex, suggesting reduced neuronal uptake.
Similar to the present findings in Slc13a5 knockout mice, increased CSF
citrate levels have been reported for SLC13A5 mutant epilepsy patients,
supporting the hypothesis that loss of SLC13A5 function alters TCA
metabolism and may disrupt metabolic compartmentation in the brain
(Bainbridge et al., 2017). Interestingly, citrate injection into the CSF
has been shown to induce seizures in rodents, which is inhibited by co-
administration of Ca2+ (Hornfeldt and Larson, 1990).
In the cytoplasm, citrate controls glycolysis by allosterically in-
hibiting the rate-limiting enzyme phosphofructokinase-1, thus
Fig. 7. A summary of the main findings of the present study and how they relate to the suggested hypotheses of Bhutia et al. (11).
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suppressing glycolysis (Ros and Schulze, 2013). Yet, this particular
function is not likely to be relevant to the pathogenesis of epilepsy,
since citrate is expected to decrease in cytoplasm upon deletion of
SLC13A5, and not increase. Accordingly, when we deleted the trans-
porter in the liver, we did not observe any decrease in glycolysis in the
liver (Birkenfeld et al., 2011). In the brain, metabolic pathways are
compartmentalized between astrocytes and neurons, in that astrocytes
mainly can activate glycolysis and are limited in TCA cycle whereas
neurons can upregulate TCA cycle and oxidative phosphorylation with
a limited capacity of glycolysis. Consequently, astrocytes take up glu-
cose and metabolize it to lactate, which is then released into the ex-
tracellular space for subsequent uptake by neurons for use in energy
production (Magistretti and Allaman, 2015). In the mouse brain,
SLC13A5 is expressed both by neurons and astrocytes (Lamp et al.,
2011; Pajor, 2014). Our data show increased citrate and decreased
lactate levels in CSF of Slc13a5−/− mice, which could point to an in-
hibition of glycolysis by elevated citrate in astrocytes.
Citrate might serve as a significant source of energy in neurons, and
NaCT loss of function may induce an energy deficit, similar to the liver
(Birkenfeld et al., 2011). Energy deficit in neurons caused by low cy-
toplasmatic citrate levels in brain parenchyma as found in the present
study formed the basis of the interneuron energy hypothesis proposed
by Bhutia et al. (2017), because inhibitory interneurons have a higher
energy metabolism than principal neurons (Kann, 2016). If an energy
deficit is generated in inhibitory neurons through reduced cytoplasmic
citrate, the ability of inhibitory neurons to modulate glutamatergic
excitation would be impaired, which would result in enhanced seizure
susceptibility as observed here.
Deletion or inhibition of SLC13A5, thus inhibiting citrate uptake,
has been shown to reduce fatty acid synthesis in hepatocytes and liver
tissue (Birkenfeld et al., 2011; Pesta et al., 2015; von Loeffelholz et al.,
2017). Citrate is a source of carbon in the biosynthesis of fatty acids and
cholesterol, and involved in the generation of the neurotransmitters
glutamate and GABA, and in acetylation of histones and non-histone
proteins (Iacobazzi and Infantino, 2014; Bhutia et al., 2017). A decrease
in the cytoplasmic levels of citrate as a consequence of SLC13A5 dele-
tion or inhibition in the brain may lead to decreased synthesis of fatty
acids and cholesterol, which might interfere with neuronal myelination
(Bhutia et al., 2017). Yet, our study showed normal myelination pat-
terns in Slc13a5−/− mice. Therefore, this explanation seems unlikely to
account for the epileptic phenotype associated with Slc13a5 deletion.
Citrate is a potent chelator of divalent cations, including Mg2+ and
Ca2+, and particularly Zn2+ (Field et al., 1975; Glusker, 1980). The
NR2A subunit of the glutamatergic NMDA receptor possesses a high-
affinity allosteric binding site for zinc (Paoletti et al., 1997; Amico-
Ruvio et al., 2011; Romero-Hernandez et al., 2016). Occupation of this
high affinity site by Zn2+ has an inhibitory effect on NMDA receptor
function. By studying the chelating effects of zinc on NMDA receptor
function, it has been reported that co-application of citrate with free
zinc enhances NMDA receptor-mediated currents (Westergaard et al.,
1995). Therefore, the idea that zinc chelation could potentiate NMDA
receptor function at central glutamatergic synapses is a plausible me-
chanism that could explain how elevated extracellular citrate levels (as
indicated by increased CSF citrate levels) may lead to enhanced NMDA
receptor-mediated synaptic transmission (Bhutia et al., 2017). Indeed,
as discussed above, molecular mechanisms underlying the hyperexcit-
ability change seen in the hippocampal slices of Slc13a5−/−mice could
include NMDA receptors.
In line with increased glutamatergic transmission, we observed in-
creased CSF concentrations of glutamate and aspartate in Slc13a5−/−
mice. Glutamate can arise from citrate in the cytoplasm by the se-
quential actions of aconitase, isocitrate dehydrogenase and transami-
nases; all of these enzyme activities are present not only in the mi-
tochondrial matrix but also in the cytoplasm. GAD would then convert
glutamate into GABA in GABAergic neurons. Dysfunction of this GABA-
generating enzyme is associated with epilepsy in mice (Kash et al.,
1997). Although we could not find differences in GABA levels in hip-
pocampus and parahippocampal cortex tissue by metabolomic analyses,
proteomic findings pointed to alterations in GABA synthesis, release
and degradation in hippocampal tissue. However, the fact that the
GABA synthesizing enzyme GAD65 is upregulated in Slc13a5−/− mice
indicates that these alterations may rather reflect compensatory
changes. In this respect, it is interesting to note that patients with
SLC13A5 mutations exhibited some improvement in seizures by GA-
BAergic antiepileptic drugs, including benzodiazepines and pheno-
barbital (Klotz et al., 2016).
Altered TCA cycle may also result in reduced ATP and adenosine
levels, which would then result in reduced activation of adenosine A1
receptors with consequences of potassium channel regulation and re-
sulting neuronal hyperexcitability (Shetty et al., 2012). This would
contribute to the electrophysiological findings in Slc13a5−/− mice. It
may also explain that the use of the ketogenic diet, a high-fat, low-
carbohydrate diet was reported to be beneficial for seizure control or
level of alertness and development in patients with SLC13A5 mutations
(Hardies et al., 2015), although also worsening of the disease has been
reported (Klotz et al., 2016).
Further molecular alterations indicated by large-scale proteomic
analysis may reflect either additional compensatory mechanisms or
pathophysiological mechanisms contributing to seizure susceptibility.
In the hippocampus of Slc13a5−/− mice, enzymes involved in de-
gradation of monoamines including serotonin exhibited lowered ex-
pression levels. These proteome alterations may point to an activation
of endogenous anticonvulsant mechanisms as a consequence of seizure
activity. In this respect it is interesting to note that preclinical and
clinical data on fenfluramine, which enhances release and inhibits re-
uptake of serotonin, suggest that increasing serotonin concentrations
can prevent ictogenesis (Schoonjans and Ceulemans, 2019).
Extracellular matrix reorganization and dysregulation of lipid and
lipoprotein metabolism are discussed as putative contributors to epi-
leptogenesis and ictogenesis (Nistico and De Sarro, 1991; Pitkänen
et al., 2014; Walker et al., 2016; Keck et al., 2018; Li et al., 2018). Thus,
respective expression alterations identified in the parahippocampal
cortex of Slc13a5−/− mice may contribute to enhanced excitability.
In theory, because SLC13A5 is also abundantly expressed in the
liver, secondary contributing effects from altered liver metabolism
might also play a role for the brain phenotype following SLC13A5 de-
letion as observed here. However, as previously reported by us for
Slc13a5−/− mice, liver histology is normal in these mice, high fat diet
fed Slc13a5−/− mice are protected from the non-alcoholic fatty liver
disease that develops in the wild type mice, and Slc13a5−/− mice have
increased levels of ketone bodies (due to an increase in hepatic lipid
oxidation), which are in general regarded as protective against seizures
(Birkenfeld et al., 2011). Thus, while we cannot completely exclude the
possibility that peripheral metabolic changes contribute to the brain
phenotype reported here, our previous data make it unlikely.
In summary, our data suggest that deletion of Slc13a5 in mice
contributes to an epileptic phenotype, reflecting the situation in the
recently identified patients with loss-of-function SLC13A5 mutations.
The metabolomic data indicate that extracellular and intracellular ci-
trate levels in the brain are involved in the observed epilepsy phenotype
in mutant mice, substantiating the cytoplasmic citrate deficit hypoth-
esis suggested by Bhutia et al. (2017), but also the zinc chelation and
interneuron energy hypotheses suggested by the latter authors (Fig. 7).
Since seizures and status epilepticus occurring in patients with
SLC13A5 mutations are typically resistant to available therapies (Klotz
et al., 2016), the current mouse model provides a tool for further un-
derstanding the pathophysiology of seizures in response to SLC13A5
mutations and developing novel, more effective therapies for this severe
type of early infantile epileptic encephalopathy.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.nbd.2020.105018.
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